clinical trial · NCT06179160
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Solid TumorsINCB161734CetuximabRetifanlimabGEMNabPmFOLFIRINOXFOLFOXFOLFIRIINCA33890
brief summary
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
started
Jan 4, 2024
primary completion
Jan 1, 2027
completion
Jan 1, 2027
last updated
Jul 22, 2026
official title
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol